• 
  A.S. Cottereau, L. Rebaud, J. Trotman, P. Feugier, L.J. Nastoupil, et al.. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial. Annals of Oncology, 2024, 35 (1), pp.130-137. ⟨10.1016/j.annonc.2023.10.121⟩. ⟨inserm-04778050⟩
• 
  Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, et al.. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Advances, 2023, 7 (14), pp.3735-3738. ⟨10.1182/bloodadvances.2023009911⟩. ⟨hal-04239554⟩
• 
  Florence Nguyen-Khac, Marine Baron, Romain Guièze, Pierre Feugier, Alexandra Fayault, et al.. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study). British Journal of Haematology, 2024, 205 (2), pp.495-502. ⟨10.1111/bjh.19459⟩. ⟨hal-04796762⟩
• 
  Kamel Laribi, Alix Baugier de Materre, David Ghez, Caroline Dartigeas, Cécile Tomowiak, et al.. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy. HemaSphere, 2022, 6 (6), pp.e716. ⟨10.1097/hs9.0000000000000716⟩. ⟨inserm-04783476⟩
• 
  Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, et al.. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. Journal of Clinical Oncology, 2022, 40 (28), pp.3239-3245. ⟨10.1200/JCO.22⟩. ⟨inserm-04783079⟩
• 
  Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
• 
  V. Camus, R. Houot, G. Brisou, B. Tessoulin, S. Bailly, et al.. Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.. Blood Advances, 2024, 8 (20), pp.5371-5381. ⟨10.1182/bloodadvances.2024013726⟩. ⟨hal-04708799⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine, 2024, 391 (9), pp.789-799. ⟨10.1056/NEJMoa2403394⟩. ⟨inserm-04761524⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2665-2665. ⟨10.1038/s41591-023-02624-w⟩. ⟨hal-04755672⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2024, 30 (7), pp.2089 - 2089. ⟨10.1038/s41591-024-03053-z⟩. ⟨hal-04753011⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Jérémie Calais, Agathe Edet-Sanson, Stephane Gaucher, Pierre Vera, Joseph Le Cloirec. Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting Candida albicans Tricuspid Endocarditis. The quarterly journal of nuclear medicine and molecular imaging, 2015, pp.1-8. ⟨10.1007/s13139-015-0333-5⟩. ⟨hal-01145000⟩
• 
  Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, et al.. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplantation, 2023, Bone Marrow Transplantation, 58 (5), pp.534-543. ⟨10.1038/s41409-023-01931-7⟩. ⟨hal-04672661⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Christian Borel, Xu-Shan Sun, Alexandre Coutte, Guillaume Bera, Christian Sire, et al.. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiotherapy & Oncology, 2024, 197, pp.110329. ⟨10.1016/j.radonc.2024.110329⟩. ⟨hal-04586362⟩
• 
  Loic Renaud, Juliette Wencel, Arnaud Pagès, Ahmad Al Jijakli, Hannah Moatti, et al.. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma. Haematologica, 2024, ⟨10.3324/haematol.2023.284689⟩. ⟨inserm-04671855⟩
• 
  A. Le Cesne, J. Y. Blay, D. Cupissol, A. Italiano, C. Delcambre, et al.. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Annals of Oncology, 2021, Annals of Oncology, 32 (8), p. 1034-1044. ⟨10.1016/j.annonc.2021.04.014⟩. ⟨hal-04522981⟩
• 
  Gilles Crochet, Gloria Iacoboni, Audrey Couturier, Emmanuel Bachy, Josu Iraola-Truchuelo, et al.. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.. Blood, 2024, ⟨10.1182/blood.2024024526⟩. ⟨hal-04607118⟩
• 
  Cédric Rossi, Marc André, Jehan Dupuis, Franck Morschhauser, Bertrand Joly, et al.. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.. Haematologica, 2022, Haematologica, 107 (12), pp.2897-2904. ⟨10.3324/haematol.2021.280004⟩. ⟨hal-04609851⟩
• 
  Marie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, Olivier Rigal, Johan Le Fel, et al.. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI: Journal of the National Cancer Institute, 2022, 115 (3), pp.322-331. ⟨10.1093/jnci/djac240⟩. ⟨hal-03992251⟩

126

420